Search Results for: lupus nephritis

FDA Accepts Application for Potential Treatment for Lupus Nephritis, Gazyva®

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is eager to share exciting news. The U.S. Food and Drug Administration accepted the supplemental Biologics License Application (sBLA) from Genentech for Gazyva® (obinutuzumab) as a potential treatment of lupus nephritis. The acceptance is based on results from the Phase 3 REGENCY study showing improved complete renal FDA Accepts Application for Potential Treatment for Lupus Nephritis, Gazyva®

Obinutuzumab Showed Significantly Positive Results in Published Phase III Lupus Nephritis Study

Exciting breaking news: A paper published in the highly prestigious journal New England Journal of Medicine and presented at the World Congress of Nephrology reported that results of the Phase III REGENCY trial found that among people with active lupus nephritis, Gazyva® (obinutuzumab) plus standard therapy demonstrated statistically significant and clinically meaningful improvement in the Obinutuzumab Showed Significantly Positive Results in Published Phase III Lupus Nephritis Study

ACR Released a Summary of the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis

The American College of Rheumatology (ACR) released a summary of the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis during ACR Convergence 2024. “This is the College’s first lupus nephritis guideline since 2012 and provides evidence-based, expert guidance for the condition in adults and children.” Lupus Therapeutics, clinical affiliate of the Lupus ACR Released a Summary of the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis

Gazyva® Shows Positive Results in Phase 3 Lupus Nephritis Trial

The Lupus Research Alliance (LRA) and clinical research affiliate Lupus Therapeutics (LT) are excited to share positive news of the Phase 3 REGENCY clinical trial showing benefits of Gazyva® (obinutuzumab) in treating people with active lupus nephritis (inflammation of the kidney associated with lupus). In development as a potential treatment for lupus nephritis, Gazyva is approved in Gazyva® Shows Positive Results in Phase 3 Lupus Nephritis Trial

Lupus Therapeutics Announces Collaboration to Support the Evaluation of Non-Genetically Modified Cell-Based Therapy for Lupus Nephritis with Artiva Biotherapeutics

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announced a collaboration with Artiva Biotherapeutics, Inc. on a Phase 1 trial of the company novel NK cell-based therapy AlloNK® (also known as AB-101), in combination with anti-CD20 antibodies, for patients with active lupus nephritis – inflammation of the kidneys caused by lupus. AlloNK Lupus Therapeutics Announces Collaboration to Support the Evaluation of Non-Genetically Modified Cell-Based Therapy for Lupus Nephritis with Artiva Biotherapeutics

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing the engineered natural killer (NK) cell therapy NKX019 for refractory lupus nephritis that has not responded to standard treatment. Lupus Therapeutics has provided advisory services and will support Nkarta in early Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Lupus Therapeutics Partners to Evaluate Potential Treatment for SLE and Lupus Nephritis Through North American Trial Network

Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis.  Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, will help Novartis Pharmaceuticals Corporation (Novartis) conduct the trials through the Lupus Clinical Investigators Network (LuCIN) at Lupus Therapeutics Partners to Evaluate Potential Treatment for SLE and Lupus Nephritis Through North American Trial Network

Great News for Lupus Nephritis Treatment: Itolizumab Fast-Tracked by FDA

The Lupus Research Alliance (LRA) is pleased to share that a potential new treatment in development by Equillium, Inc. for lupus nephritis, itolizumab, was granted Fast Track designation by the U.S. Food and Drug Administration.  As defined by the FDA, this designation is “designed to facilitate the development, and expedite the review of drugs to Great News for Lupus Nephritis Treatment: Itolizumab Fast-Tracked by FDA

LRA Spotlight on ACR Convergence 2024: Lupus Therapeutics-Supported Clinical Research and More

New ACR guidelines for advancing the management of lupus nephritis (LN). Novel approaches and promising data from early- to late-stage lupus treatments in development, including CAR T cell therapies. Strategies for promoting equity in lupus clinical trials. These were among the key presentations at ACR (American College of Rheumatology) Convergence 2024. Lupus Therapeutics (LT), the LRA Spotlight on ACR Convergence 2024: Lupus Therapeutics-Supported Clinical Research and More

Lupus Research Alliance Announces Lupus Research Highlights at ACR Convergence 2024

Two reports by Lupus Therapeutics, the clinical affiliate of the LRA, and the Lupus Clinical Investigators Network (LuCIN), on promoting equity in lupus clinical trials, and identifying trial barriers and solutions The Lupus Research Alliance (LRA), the largest private funder of lupus research worldwide, today announced that 34 presentations, including research funded by the organization Lupus Research Alliance Announces Lupus Research Highlights at ACR Convergence 2024

Promising New Lupus Treatments Highlighted ACR Annual Meeting

Results of clinical trials testing potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2020. These studies include phase I trials, which test for side effects and a safe dosage; larger phase II trials, which test for effectiveness and further gauge safety; and large phase III trials, which confirm Promising New Lupus Treatments Highlighted ACR Annual Meeting

Breadth of Clinical Research Presented at the 2019 ACR/ARP Annual Meeting Brings Hope for New Lupus Treatments

The Lupus Research Alliance staff was on the ground at the 2019 ACR/ARP Annual Meeting and highly encouraged by the positive results reported for several potential new treatments that may help people with lupus. “The foundational work the Lupus Research Alliance and others have supported is beginning to bear fruit with potential therapies like anifrolumab, Breadth of Clinical Research Presented at the 2019 ACR/ARP Annual Meeting Brings Hope for New Lupus Treatments